Skip to main
amwpeptides Three peptides. A wider set of measurements.

Tesamorelin studies and FDA approval at amwpeptides

Visceral fat and liver fat are specific measurements. Their clinical setting matters just as much.

The JAMA fat measurements

The 2014 JAMA randomized trial enrolled 50 antiretroviral-treated adults with HIV and abdominal fat accumulation. Over six months, the treatment effect on visceral fat was -42 cm² (P=0.005), and the net effect on hepatic lipid was -2.9 percentage points (P=0.003). Visceral fat sits around the abdominal organs; hepatic fat is fat in the liver.

I prefer fat measurements with their anatomical locations attached. The measurements describe particular deposits in a particular population. The -42 cm² figure is the treatment effect relative to placebo, rather than the change within the tesamorelin arm alone. That distinction changes what the number says.

An imaging technician at a console beside an empty scanner room
An imagined imaging workspace for an article about internal fat measurements, rather than a depiction of the trial.

What it is

Tesamorelin is a synthetic 44-amino-acid GHRH analogue with an N-terminal modification that resists enzymatic cleavage. It stimulates the pituitary's own growth hormone release. The NIH LiverTox monograph describes its U.S. approval in 2010 for reducing excess abdominal fat in HIV-infected adults with lipodystrophy.

This is the compound here with completed Phase 3 evidence for that specific indication. For this indication, the completed HIV clinical program gives a stronger basis for confidence than a similar receptor mechanism. An approved pharmaceutical product and laboratory research material also carry different oversight; the research-grade material lacks the purity and potency oversight of the approved product.

CLINICAL ACCESS BOUNDARY

Keep research supply separate from care

Sermorelin is now among the medicines Promise Peptides prescribes at mypromise.com; its U.S.-licensed clinicians make an individual judgment about each request. Its clinicians can refuse a request, and its prescription-only care is confined to U.S. patients, with both state rules and the treatment determining its options. Its compounded sermorelin has no FDA approval. Laboratory-labelled material is still sold for research, separately from that clinical route.

Pooled outcomes and withdrawal

A 2026 meta-analysis of five randomized trials in HIV-associated lipodystrophy reported a mean difference in visceral adipose tissue of -27.71 cm² (95% CI: -38.37 to -17.06; P<0.001). It also reported trunk fat lower by 1.18 kg, hepatic fat fraction lower by 4.28 percentage points and lean body mass higher by 1.42 kg. These are separate outcomes with different units.

The 52-week tesamorelin program reported a sustained -18% visceral fat change (P<0.001 versus baseline), with reaccumulation after discontinuation. Glucose changes across that program were not clinically significant. I take visceral fat reaccumulation seriously: it changes how the durability of the effect must be described. It also makes long-term tolerability an especially important unanswered question.

Glucose and other safety findings

In 13 healthy men studied for two weeks, IGF-1 rose by 181 micrograms/liter (P<0.0001), while fasting glucose (P=0.93) and insulin-stimulated glucose uptake (P=0.61) were not significantly affected. That short result offers limited reassurance about the measured interval. People with dysglycemia bring a different safety question.

Clinical cautions include local injection reactions, elevated IGF-1 and glucose effects in susceptible individuals. Active malignancy is a labeled contraindication. The trials' observation periods leave long-term oncologic safety unresolved. LiverTox rates clinically apparent liver injury as unlikely, with likelihood score E and no attributable liver-injury cases reported in its account. A favorable liver-safety assessment answers that organ-specific question; it leaves the other cautions standing.